<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172820</url>
  </required_header>
  <id_info>
    <org_study_id>CRINCN9874</org_study_id>
    <secondary_id>P20GM103644</secondary_id>
    <nct_id>NCT02172820</nct_id>
  </id_info>
  <brief_title>Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees</brief_title>
  <official_title>Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participation in outpatient cardiac rehabilitation (CR) decreases morbidity and mortality for
      patients hospitalized with myocardial infarction, coronary bypass surgery or percutaneous
      revascularization. Unfortunately, only 10-35% of patients for whom CR is indicated choose to
      participate. Medicaid coverage and similar state-supported insurance are robust predictors of
      CR non-participation. There is growing recognition of the need to increase CR among patients
      with this form of insurance and other economically disadvantaged patients, but there are no
      evidence-based interventions available for doing so. In the present study we are examining
      the efficacy of using financial incentives for increasing CR participation among Medicaid
      patients. Financial incentives have been highly effective in altering other health behaviors
      among disadvantaged populations (e.g., smoking during pregnancy, weight loss). For this study
      are randomizing 130 CR-eligible Medicaid enrollees to a treatment condition where they
      receive financial incentives contingent on initiation of and continued attendance at CR
      sessions or to a &quot;usual-care&quot; condition where they will not receive these incentives.
      Treatment conditions will be compared on attendance at CR and end-of-intervention
      improvements in fitness, decision making and health-related quality of life. Cost
      effectiveness of the treatment conditions will also be examined by comparing the costs of the
      incentive intervention and usual care conditions with their effects on increasing CR
      initiation and adherence. Should this intervention be efficacious and cost-effective, it has
      the potential to substantially increase CR participation and significantly improve health
      outcomes among low-income cardiac patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attendance at Cardiac Rehabilitation Exercise Sessions</measure>
    <time_frame>Within 4 months of initial stress test</time_frame>
    <description>The number of patients who completed cardiac rehabilitation (CR) as defined as greater than or equal to 30 sessions. Must have been completed within 4 months of the entry stress test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Health</measure>
    <time_frame>Intake, 4 months</time_frame>
    <description>Secondary outcomes included changes between baseline and 4-month assessment in fitness (peak oxygen uptake directly measured by expired gas analysis or estimated by metabolic equivalents), body composition (body mass index, waist circumference), and quality of life (MacNew).The MacNew was designed to evaluate how daily activities and physical,emotional and social functioning are affected by heart disease and its treatment. It consists of 27 questions grouped into 3 domains: physical, mental and social functioning. Both subscales and summary score are interpreted as scores between 1 and 7; higher scores are better, and a change of at least 0.5 is a useful indicator of the minimal important difference.Changes over time were assessed using paired differences in scores from intake to four months. Due to non-normal distributions, Wilcoxon Signed Rank Test was used. Contributions of other variables to changes in secondary outcomes were examined using analyses of covariance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Mental Health/Cognition</measure>
    <time_frame>Changes in socio-cognitive measures will be measures from intake to completion of intervention (4 months)</time_frame>
    <description>The Achenbach System of Empirically Based Assessment (ASEABA) is an integrated system of multi-informant assessments, including self-reports, to measure adaptive functioning and problems. The problem items have been factor-analytically reduced to 8 syndrome scales that are consistent across age, informant and culture. Higher scores represent higher symptoms (e.g. emotional/behavioral problems). The Stop Signal Reaction Time (SSRT) task measures the ability to inhibit incorrect responses. Lower scores represent a better ability to inhibit reactions. The BRIEF-A is a rating scale developed to look at everyday behaviors associated with specific domains of executive functions in adults ages 18-90.T-scores (standardized scores) are used to interpret the individual's level of executive functioning (EF). Higher scores represent more self-reported problems. A score of 50 represents the mean.A difference of 10 from the mean indicates a difference of one standard deviation (SD).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maintenance of Physical Health Gains Following Intervention.</measure>
    <time_frame>4 months and 1 year.</time_frame>
    <description>Changes in measures of physical health and fitness (peak oxygen uptake, metabolic equivalents, waist circumference, BMI, treadmill time, smoking status, perceived quality of life) will be measured from completion of intervention (4 months) to 8 months later (1 year follow-up).</description>
  </other_outcome>
  <other_outcome>
    <measure>Maintenance of Mental Health/Cognition Scores Following Intervention.</measure>
    <time_frame>4 months and 1 year.</time_frame>
    <description>Changes in measures of mental health (Beck Depression Inventory, Adult Self-Report) as well as changes in measures of executive function (Trail Making and Tower tasks, Delay Discounting, Time Perspective Questionnaire, Stop Signal Task, Behavior Rating Inventory of Executive Function) will be measured from completion of intervention (4 months) to 8 months later (1 year follow-up).</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Care Costs</measure>
    <time_frame>From intake to one year follow-up</time_frame>
    <description>Health care costs (cost of delivering care at the cardiac rehabilitation clinic as well as hospital costs) will be calculated from study entry to one year follow-up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Costs of Attending Care</measure>
    <time_frame>Intake to 1 year follow-up</time_frame>
    <description>Costs to the patient of attending care (transportation, child/elder care, missed wages) will be calculated from study entry to one year follow-up.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Financial incentives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive financial incentives for completing exercise sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Financial incentives</intervention_name>
    <description>Patients in the experimental group will receive financial incentives for completing exercise sessions.</description>
    <arm_group_label>Financial incentives</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A recent myocardial infarction, percutaneous coronary intervention, coronary artery
             bypass graft, heart valve replacement or repair, or stable heart failure.

          -  Enrolled in a state-supported insurance plan for low income individuals

          -  Lives in and plans to remain in the greater Burlington, Vermont area (Chittenden
             County) for the next 12 mos.

        Exclusion criteria:

          -  Dementia (MMSE&lt;20) or current untreated Axis 1 psychiatric disorder other than
             nicotine dependence as determined by medical history

          -  Non-English speaking

          -  Prior participation in cardiac rehabilitation

          -  Advanced cancer, advanced frailty, or other longevity-limiting systemic disease that
             would preclude CR participation

          -  Rest angina or very low threshold angina (&lt;2 METS) until adequate therapy is
             instituted

          -  Severe life threatening ventricular arrhythmias unless adequately controlled (e.g.
             intracardiac defibrillator)

          -  Class 4 chronic heart failure (symptoms at rest)

          -  Exercise-limiting non-cardiac disease such as severe arthritis, past stroke, severe
             lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <results_first_submitted>February 26, 2019</results_first_submitted>
  <results_first_submitted_qc>May 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2019</results_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Diann Gaalema</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cardiac rehabilitation</keyword>
  <keyword>contingency management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02172820/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02172820/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02172820/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Financial Incentives</title>
          <description>Participants receive financial incentives for completing exercise sessions.
Financial incentives: Patients in the experimental group will receive financial incentives for completing exercise sessions.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Financial Incentives</title>
          <description>Participants receive financial incentives for completing exercise sessions.
Financial incentives: Patients in the experimental group will receive financial incentives for completing exercise sessions.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="11.0"/>
                    <measurement group_id="B2" value="55.8" spread="9.2"/>
                    <measurement group_id="B3" value="57.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Attendance at Cardiac Rehabilitation Exercise Sessions</title>
        <description>The number of patients who completed cardiac rehabilitation (CR) as defined as greater than or equal to 30 sessions. Must have been completed within 4 months of the entry stress test.</description>
        <time_frame>Within 4 months of initial stress test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Financial Incentives</title>
            <description>Participants receive financial incentives for completing exercise sessions.
Financial incentives: Patients in the experimental group will receive financial incentives for completing exercise sessions.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Attendance at Cardiac Rehabilitation Exercise Sessions</title>
          <description>The number of patients who completed cardiac rehabilitation (CR) as defined as greater than or equal to 30 sessions. Must have been completed within 4 months of the entry stress test.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Health</title>
        <description>Secondary outcomes included changes between baseline and 4-month assessment in fitness (peak oxygen uptake directly measured by expired gas analysis or estimated by metabolic equivalents), body composition (body mass index, waist circumference), and quality of life (MacNew).The MacNew was designed to evaluate how daily activities and physical,emotional and social functioning are affected by heart disease and its treatment. It consists of 27 questions grouped into 3 domains: physical, mental and social functioning. Both subscales and summary score are interpreted as scores between 1 and 7; higher scores are better, and a change of at least 0.5 is a useful indicator of the minimal important difference.Changes over time were assessed using paired differences in scores from intake to four months. Due to non-normal distributions, Wilcoxon Signed Rank Test was used. Contributions of other variables to changes in secondary outcomes were examined using analyses of covariance.</description>
        <time_frame>Intake, 4 months</time_frame>
        <population>Despite having 65 subjects in each of the two groups (financial incentives and control), only 55 and 57 subjects were analyzed respectively. Not every subject completed the initial intake (lost contact with 10 and 8 subjects, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Financial Incentives</title>
            <description>Participants receive financial incentives for completing exercise sessions.
Financial incentives: Patients in the experimental group will receive financial incentives for completing exercise sessions.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Health</title>
          <description>Secondary outcomes included changes between baseline and 4-month assessment in fitness (peak oxygen uptake directly measured by expired gas analysis or estimated by metabolic equivalents), body composition (body mass index, waist circumference), and quality of life (MacNew).The MacNew was designed to evaluate how daily activities and physical,emotional and social functioning are affected by heart disease and its treatment. It consists of 27 questions grouped into 3 domains: physical, mental and social functioning. Both subscales and summary score are interpreted as scores between 1 and 7; higher scores are better, and a change of at least 0.5 is a useful indicator of the minimal important difference.Changes over time were assessed using paired differences in scores from intake to four months. Due to non-normal distributions, Wilcoxon Signed Rank Test was used. Contributions of other variables to changes in secondary outcomes were examined using analyses of covariance.</description>
          <population>Despite having 65 subjects in each of the two groups (financial incentives and control), only 55 and 57 subjects were analyzed respectively. Not every subject completed the initial intake (lost contact with 10 and 8 subjects, respectively).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% change BMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="-1.35" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.87" lower_limit="-1.52" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change VO2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" lower_limit="3.68" upper_limit="12.30"/>
                    <measurement group_id="O2" value="12.54" lower_limit="6.01" upper_limit="21.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change Waist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" lower_limit="-3.02" upper_limit="0.67"/>
                    <measurement group_id="O2" value="-0.23" lower_limit="-2.32" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change cardiac-specific quality of life (MacNew)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" lower_limit="3.70" upper_limit="14.53"/>
                    <measurement group_id="O2" value="10.73" lower_limit="6.68" upper_limit="18.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Mental Health/Cognition</title>
        <description>The Achenbach System of Empirically Based Assessment (ASEABA) is an integrated system of multi-informant assessments, including self-reports, to measure adaptive functioning and problems. The problem items have been factor-analytically reduced to 8 syndrome scales that are consistent across age, informant and culture. Higher scores represent higher symptoms (e.g. emotional/behavioral problems). The Stop Signal Reaction Time (SSRT) task measures the ability to inhibit incorrect responses. Lower scores represent a better ability to inhibit reactions. The BRIEF-A is a rating scale developed to look at everyday behaviors associated with specific domains of executive functions in adults ages 18-90.T-scores (standardized scores) are used to interpret the individual's level of executive functioning (EF). Higher scores represent more self-reported problems. A score of 50 represents the mean.A difference of 10 from the mean indicates a difference of one standard deviation (SD).</description>
        <time_frame>Changes in socio-cognitive measures will be measures from intake to completion of intervention (4 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Financial Incentives</title>
            <description>Participants receive financial incentives for completing exercise sessions.
Financial incentives: Patients in the experimental group will receive financial incentives for completing exercise sessions.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Mental Health/Cognition</title>
          <description>The Achenbach System of Empirically Based Assessment (ASEABA) is an integrated system of multi-informant assessments, including self-reports, to measure adaptive functioning and problems. The problem items have been factor-analytically reduced to 8 syndrome scales that are consistent across age, informant and culture. Higher scores represent higher symptoms (e.g. emotional/behavioral problems). The Stop Signal Reaction Time (SSRT) task measures the ability to inhibit incorrect responses. Lower scores represent a better ability to inhibit reactions. The BRIEF-A is a rating scale developed to look at everyday behaviors associated with specific domains of executive functions in adults ages 18-90.T-scores (standardized scores) are used to interpret the individual's level of executive functioning (EF). Higher scores represent more self-reported problems. A score of 50 represents the mean.A difference of 10 from the mean indicates a difference of one standard deviation (SD).</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% change ASEABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" lower_limit="-6.68" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="1.03" lower_limit="-1.72" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change SSRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" lower_limit="-4.87" upper_limit="25.25"/>
                    <measurement group_id="O2" value="16.10" lower_limit="-1.17" upper_limit="36.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change BRIEF - A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" lower_limit="-11.27" upper_limit="-3.57"/>
                    <measurement group_id="O2" value="0.97" lower_limit="-3.62" upper_limit="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maintenance of Physical Health Gains Following Intervention.</title>
        <description>Changes in measures of physical health and fitness (peak oxygen uptake, metabolic equivalents, waist circumference, BMI, treadmill time, smoking status, perceived quality of life) will be measured from completion of intervention (4 months) to 8 months later (1 year follow-up).</description>
        <time_frame>4 months and 1 year.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maintenance of Mental Health/Cognition Scores Following Intervention.</title>
        <description>Changes in measures of mental health (Beck Depression Inventory, Adult Self-Report) as well as changes in measures of executive function (Trail Making and Tower tasks, Delay Discounting, Time Perspective Questionnaire, Stop Signal Task, Behavior Rating Inventory of Executive Function) will be measured from completion of intervention (4 months) to 8 months later (1 year follow-up).</description>
        <time_frame>4 months and 1 year.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Care Costs</title>
        <description>Health care costs (cost of delivering care at the cardiac rehabilitation clinic as well as hospital costs) will be calculated from study entry to one year follow-up.</description>
        <time_frame>From intake to one year follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Costs of Attending Care</title>
        <description>Costs to the patient of attending care (transportation, child/elder care, missed wages) will be calculated from study entry to one year follow-up.</description>
        <time_frame>Intake to 1 year follow-up</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Emergency Department (ED) visits and hospitalizations were pulled from the medical record</desc>
      <group_list>
        <group group_id="E1">
          <title>Financial Incentives</title>
          <description>Participants receive financial incentives for completing exercise sessions.
Financial incentives: Patients in the experimental group will receive financial incentives for completing exercise sessions.
39% fewer hospital contacts in the incentive condition (p=0.079)</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="65"/>
                <counts group_id="E2" events="32" subjects_affected="18" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" events="33" subjects_affected="18" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Emergency Department Visit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Racially homogenous patient population; Baseline assessments were conducted on site; Clinical staff could not be fully blinded; Hospitalizations outside University of Vermont Medical Center may have been missed; Small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Diann Gaalema, Ph.D., PI</name_or_title>
      <organization>The University of Vermont</organization>
      <phone>802-656-9874</phone>
      <email>Diann.Gaalema@med.uvm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

